Otsuka Pharmaceutical Co. won a court ruling that will prevent generic versions of the schizophrenia treatment Abilify® from entering the U.S. market until April 2015. U.S. District Judge Mary L. Cooper in Trenton, New Jersey, upheld a patent that covers aripiprazole, the key ingredient in the drug. Tokyo-based Otsuka discovered Abilify®, the sixth-biggest selling drug in the U.S., and comarkets it with BMS in the U.S. and Europe. The ruling is a loss for companies seeking to sell generic versions of the medicine. To reach her decision, Judge Cooper went through the history of schizophrenia treatments and the different compounds that are on the market. “She spent a lot of time on this matter,” said James Monroe, partner at Finnegan, who represented Otsuka and said “she gave very close consideration” to the arguments presented by both sides.
James R. Barney
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Charles T. Collins-Chase
Finnegan Client Otsuka Prevails in U.S. Abilify® Patent Litigation
November 16, 2010
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.